Our top pick for
9 Meters Biopharma Inc is a business based in the US. 9 Meters Biopharma shares (INNT) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$0.69 - $0.84|
|50-day moving average||$0.73|
|200-day moving average||$0.61|
|Wall St. target price||$10.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.49|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-193.21%|
|Return on equity TTM||0%|
|Market capitalisation||$23.1 million|
TTM: trailing 12 months
There are currently 2.2 million 9 Meters Biopharma shares held short by investors – that's known as 9 Meters Biopharma's "short interest". This figure is 1.7% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting 9 Meters Biopharma shares can be evaluated.
9 Meters Biopharma's "short interest ratio" (SIR) is the quantity of 9 Meters Biopharma shares currently shorted divided by the average quantity of 9 Meters Biopharma shares traded daily (recently around 519741.86602871). 9 Meters Biopharma's SIR currently stands at 4.18. In other words for every 100,000 9 Meters Biopharma shares traded daily on the market, roughly 4180 shares are currently held short.
However 9 Meters Biopharma's short interest can also be evaluated against the total number of 9 Meters Biopharma shares, or, against the total number of tradable 9 Meters Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 9 Meters Biopharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 9 Meters Biopharma shares in existence, roughly 30 shares are currently held short) or 0.027% of the tradable shares (for every 100,000 tradable 9 Meters Biopharma shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against 9 Meters Biopharma.
Find out more about how you can short 9 Meters Biopharma stock.
We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months.
9 Meters Biopharma's shares were split on a 1:10 basis on 31 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for 9 Meters Biopharma shares which in turn could have impacted 9 Meters Biopharma's share price.
Over the last 12 months, 9 Meters Biopharma's shares have ranged in value from as little as $0.6858 up to $0.835. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.